NASDAQ:CMTA - Clementia Pharmaceuticals Stock Price, Price Target & More

$19.44 +1.04 (+5.65 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$18.40
Today's Range$17.30 - $19.50
52-Week Range$11.72 - $20.15
Volume41,389 shs
Average Volume69,363 shs
Market Capitalization$517 million
P/E Ratio-2.45
Dividend YieldN/A
BetaN/A

About Clementia Pharmaceuticals (NASDAQ:CMTA)

Clementia Pharmaceuticals logoClementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. Its lead product candidate is palovarotene, an oral small molecule that binds and activates retinoic acid receptor gamma, and prevents abnormal new bone formation, as well as scar tissue formation in various tissues in animal models. The company is developing palovarotene for the treatment of fibrodysplasia ossificans progressiva and multiple osteochondroma, as well as has one Phase III and Phase II/III trials for two separate indications. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.

Receive CMTA News and Ratings via Email

Sign-up to receive the latest news and ratings for CMTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CMTA
CUSIPN/A
Phone514-940-3600

Debt

Debt-to-Equity RatioN/A
Current Ratio10.68%
Quick Ratio10.68%

Price-To-Earnings

Trailing P/E Ratio-2.45
Forward P/E Ratio-14.62
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.47 per share
Price / Book4.35

Profitability

EPS (Most Recent Fiscal Year)($7.93)
Net Income$-115,450,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-117.13%

Miscellaneous

Employees30
Outstanding Shares31,720,000

How to Become a New Pot Stock Millionaire

Clementia Pharmaceuticals (NASDAQ:CMTA) Frequently Asked Questions

What is Clementia Pharmaceuticals' stock symbol?

Clementia Pharmaceuticals trades on the NASDAQ under the ticker symbol "CMTA."

How were Clementia Pharmaceuticals' earnings last quarter?

Clementia Pharmaceuticals (NASDAQ:CMTA) posted its earnings results on Wednesday, February, 28th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.03. View Clementia Pharmaceuticals' Earnings History.

When is Clementia Pharmaceuticals' next earnings date?

Clementia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 23rd 2018. View Earnings Estimates for Clementia Pharmaceuticals.

What price target have analysts set for CMTA?

5 Wall Street analysts have issued 12 month price targets for Clementia Pharmaceuticals' stock. Their predictions range from $23.00 to $32.00. On average, they expect Clementia Pharmaceuticals' share price to reach $26.60 in the next twelve months. View Analyst Ratings for Clementia Pharmaceuticals.

Who are some of Clementia Pharmaceuticals' key competitors?

Who are Clementia Pharmaceuticals' key executives?

Clementia Pharmaceuticals' management team includes the folowing people:
  • Dr. Clarissa Desjardins Ph.D., Pres, CEO & Director
  • Mr. Michael Singer CGA, CFO & Corp. Sec.
  • Dr. Donna Roy Grogan M.D., Chief Medical Officer
  • Mr. Jeffery Packman, Chief Devel. Officer
  • Mr. Eric Grinstead, Chief Commercial Officer

When did Clementia Pharmaceuticals IPO?

(CMTA) raised $101 million in an initial public offering on Wednesday, August 2nd 2017. The company issued 7,200,000 shares at $13.00-$15.00 per share. Morgan Stanley and Leerink Partners served as the underwriters for the IPO and Wedbush Securities and BTIG were co-managers.

Has Clementia Pharmaceuticals been receiving favorable news coverage?

Media headlines about CMTA stock have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Clementia Pharmaceuticals earned a news sentiment score of 0.24 on Accern's scale. They also gave news articles about the company an impact score of 45.65 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Clementia Pharmaceuticals' major shareholders?

Clementia Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include ORBIMED ADVISORS LLC (32.87%) and ORBIMED ADVISORS LLC (32.87%). View Institutional Ownership Trends for Clementia Pharmaceuticals.

How do I buy shares of Clementia Pharmaceuticals?

Shares of CMTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clementia Pharmaceuticals' stock price today?

One share of CMTA stock can currently be purchased for approximately $19.44.

How big of a company is Clementia Pharmaceuticals?

Clementia Pharmaceuticals has a market capitalization of $517 million. The company earns $-115,450,000.00 in net income (profit) each year or ($7.93) on an earnings per share basis. Clementia Pharmaceuticals employs 30 workers across the globe.

How can I contact Clementia Pharmaceuticals?

Clementia Pharmaceuticals' mailing address is 4150 ST CATHERINE STREET WEST SUITE 550, MONTREAL A8, H3Z 2Y5. The company can be reached via phone at 514-940-3600 or via email at [email protected]


MarketBeat Community Rating for Clementia Pharmaceuticals (CMTA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  85 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  171
MarketBeat's community ratings are surveys of what our community members think about Clementia Pharmaceuticals and other stocks. Vote "Outperform" if you believe CMTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMTA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Clementia Pharmaceuticals (NASDAQ:CMTA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Clementia Pharmaceuticals in the last 12 months. Their average twelve-month price target is $26.60, suggesting that the stock has a possible upside of 36.83%. The high price target for CMTA is $32.00 and the low price target for CMTA is $23.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $26.60$27.00$27.00$27.00
Price Target Upside: 36.83% upside64.43% upside64.43% upside68.64% upside

Clementia Pharmaceuticals (NASDAQ:CMTA) Consensus Price Target History

Price Target History for Clementia Pharmaceuticals (NASDAQ:CMTA)

Clementia Pharmaceuticals (NASDAQ:CMTA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2018B. RileyInitiated CoverageBuy$25.00MediumView Rating Details
11/14/2017WedbushReiterated RatingOutperform$26.00N/AView Rating Details
8/31/2017BTIG ResearchInitiated CoverageBuy -> Buy$32.00LowView Rating Details
8/28/2017Leerink SwannInitiated CoverageOutperform -> Outperform$23.00HighView Rating Details
8/28/2017Morgan StanleyInitiated CoverageOverweight -> Overweight$27.00HighView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Clementia Pharmaceuticals (NASDAQ:CMTA) Earnings History and Estimates Chart

Earnings by Quarter for Clementia Pharmaceuticals (NASDAQ:CMTA)

Clementia Pharmaceuticals (NASDAQ:CMTA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.40)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.36)($0.28)($0.32)
Q2 20182($0.38)($0.29)($0.34)
Q3 20182($0.41)($0.31)($0.36)
Q4 20182($0.43)($0.33)($0.38)

Clementia Pharmaceuticals (NASDAQ CMTA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/23/2018        
2/28/2018Q4 2017($0.34)($0.37)ViewN/AView Earnings Details
11/13/2017Q3 2017($0.31)($1.83)ViewN/AView Earnings Details
8/10/2017Q2 2017($9.54)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Clementia Pharmaceuticals (NASDAQ:CMTA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Clementia Pharmaceuticals (NASDAQ CMTA) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 68.04%
Insider Trading History for Clementia Pharmaceuticals (NASDAQ:CMTA)
Insider Trading History for Clementia Pharmaceuticals (NASDAQ:CMTA)

Clementia Pharmaceuticals (NASDAQ CMTA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Clementia Pharmaceuticals (NASDAQ CMTA) News Headlines

Source:
DateHeadline
 Brokerages Anticipate Clementia Pharmaceuticals (CMTA) Will Announce Earnings of -$0.33 Per Share Brokerages Anticipate Clementia Pharmaceuticals (CMTA) Will Announce Earnings of -$0.33 Per Share
www.americanbankingnews.com - April 2 at 7:10 PM
FY2018 Earnings Estimate for Clementia Pharmaceuticals (CMTA) Issued By B. RileyFY2018 Earnings Estimate for Clementia Pharmaceuticals (CMTA) Issued By B. Riley
www.americanbankingnews.com - March 30 at 7:05 AM
Analyst: Clementia Has Potential To Reach Unmet Market For Rare Bone DiseaseAnalyst: Clementia Has Potential To Reach Unmet Market For Rare Bone Disease
finance.yahoo.com - March 29 at 9:55 AM
Clementia Pharmaceuticals (CMTA) Given Consensus Recommendation of "Buy" by BrokeragesClementia Pharmaceuticals (CMTA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 28 at 10:17 AM
B. Riley Begins Coverage on Clementia Pharmaceuticals (CMTA)B. Riley Begins Coverage on Clementia Pharmaceuticals (CMTA)
www.americanbankingnews.com - March 28 at 8:06 AM
Zacks: Clementia Pharmaceuticals Inc (CMTA) Given Consensus Rating of "Strong Buy" by AnalystsZacks: Clementia Pharmaceuticals Inc (CMTA) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - March 23 at 1:32 AM
Clementia Pharmaceuticals (CMTA) Rating Increased to Hold at Zacks Investment ResearchClementia Pharmaceuticals (CMTA) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - March 20 at 8:16 PM
-$0.33 Earnings Per Share Expected for Clementia Pharmaceuticals Inc (CMTA) This Quarter-$0.33 Earnings Per Share Expected for Clementia Pharmaceuticals Inc (CMTA) This Quarter
www.americanbankingnews.com - March 16 at 3:06 PM
 Clementia Pharmaceuticals Inc (CMTA) Receives Average Rating of "Strong Buy" from Analysts Clementia Pharmaceuticals Inc (CMTA) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - March 8 at 3:28 AM
Zacks Investment Research Lowers Clementia Pharmaceuticals (CMTA) to SellZacks Investment Research Lowers Clementia Pharmaceuticals (CMTA) to Sell
www.americanbankingnews.com - March 7 at 8:34 PM
Sectoral Asset Management Inc Raises Stake in Clementia Pharmaceuticals Inc (CMTA)Sectoral Asset Management Inc Raises Stake in Clementia Pharmaceuticals Inc (CMTA)
www.americanbankingnews.com - March 6 at 2:11 PM
Clementia to Present at the Cowen and Company 38th Annual Health Care ConferenceClementia to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 9:24 AM
Clementia Pharmaceuticals Inc (CMTA) to Post FY2019 Earnings of ($1.67) Per Share, Wedbush ForecastsClementia Pharmaceuticals Inc (CMTA) to Post FY2019 Earnings of ($1.67) Per Share, Wedbush Forecasts
www.americanbankingnews.com - March 5 at 8:50 AM
Clementia Pharmaceuticals Inc (CMTA) Short Interest Down 60.0% in FebruaryClementia Pharmaceuticals Inc (CMTA) Short Interest Down 60.0% in February
www.americanbankingnews.com - March 4 at 1:40 AM
Brokerages Expect Clementia Pharmaceuticals Inc (CMTA) to Post ($0.31) EPSBrokerages Expect Clementia Pharmaceuticals Inc (CMTA) to Post ($0.31) EPS
www.americanbankingnews.com - March 2 at 7:12 PM
Clementia Reports 2017 Operating Results and Business HighlightsClementia Reports 2017 Operating Results and Business Highlights
finance.yahoo.com - February 28 at 4:56 PM
Zacks: Analysts Expect Clementia Pharmaceuticals Inc (CMTA) to Announce -$0.34 Earnings Per ShareZacks: Analysts Expect Clementia Pharmaceuticals Inc (CMTA) to Announce -$0.34 Earnings Per Share
www.americanbankingnews.com - February 27 at 3:16 PM
Clementia Pharmaceuticals Inc Forecasted to Post Q1 2018 Earnings of ($0.28) Per Share (CMTA)Clementia Pharmaceuticals Inc Forecasted to Post Q1 2018 Earnings of ($0.28) Per Share (CMTA)
www.americanbankingnews.com - February 23 at 10:02 AM
Clementia Pharmaceuticals Inc to Post FY2022 Earnings of $1.35 Per Share, Leerink Swann Forecasts (CMTA)Clementia Pharmaceuticals Inc to Post FY2022 Earnings of $1.35 Per Share, Leerink Swann Forecasts (CMTA)
www.americanbankingnews.com - February 22 at 4:34 PM
 Clementia Pharmaceuticals Inc (CMTA) Receives Consensus Recommendation of "Strong Buy" from Analysts Clementia Pharmaceuticals Inc (CMTA) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - February 15 at 12:46 PM
Zacks: Brokerages Anticipate Clementia Pharmaceuticals Inc (CMTA) Will Announce Earnings of -$0.34 Per ShareZacks: Brokerages Anticipate Clementia Pharmaceuticals Inc (CMTA) Will Announce Earnings of -$0.34 Per Share
www.americanbankingnews.com - February 10 at 11:08 PM
Clementia to Participate in Leerink Partners 7th Annual Global Healthcare ConferenceClementia to Participate in Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 7 at 9:11 AM
Clementia Pharmaceuticals (CMTA) vs. Its Competitors Head to Head ContrastClementia Pharmaceuticals (CMTA) vs. Its Competitors Head to Head Contrast
www.americanbankingnews.com - February 4 at 9:08 PM
Clementia Appoints Industry Veteran Pierre Legault to its Board of DirectorsClementia Appoints Industry Veteran Pierre Legault to its Board of Directors
finance.yahoo.com - January 31 at 9:20 AM
Clementia Pharmaceuticals (CMTA) Stock Rating Upgraded by Zacks Investment ResearchClementia Pharmaceuticals (CMTA) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 30 at 8:38 PM
Zacks: Clementia Pharmaceuticals Inc (CMTA) Given Average Rating of "Strong Buy" by BrokeragesZacks: Clementia Pharmaceuticals Inc (CMTA) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 30 at 7:46 AM
 Analysts Anticipate Clementia Pharmaceuticals Inc (CMTA) to Post -$0.34 EPS Analysts Anticipate Clementia Pharmaceuticals Inc (CMTA) to Post -$0.34 EPS
www.americanbankingnews.com - January 25 at 1:24 AM
Clementia Pharmaceuticals Incs Lock-Up Period To Expire  on January 29th (NASDAQ:CMTA)Clementia Pharmaceuticals Inc's Lock-Up Period To Expire on January 29th (NASDAQ:CMTA)
www.americanbankingnews.com - January 22 at 1:28 AM
Clementia Pharmaceuticals (CMTA) Downgraded to "Sell" at Zacks Investment ResearchClementia Pharmaceuticals (CMTA) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - January 15 at 10:28 PM
 Brokerages Set $27.00 Target Price for Clementia Pharmaceuticals Inc (CMTA) Brokerages Set $27.00 Target Price for Clementia Pharmaceuticals Inc (CMTA)
www.americanbankingnews.com - January 15 at 5:38 PM
 Analysts Set $27.00 Price Target for Clementia Pharmaceuticals Inc (CMTA) Analysts Set $27.00 Price Target for Clementia Pharmaceuticals Inc (CMTA)
www.americanbankingnews.com - January 10 at 1:44 AM
Zacks: Clementia Pharmaceuticals Inc (CMTA) Receives Consensus Recommendation of "Strong Buy" from BrokeragesZacks: Clementia Pharmaceuticals Inc (CMTA) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - December 26 at 9:52 AM
Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans ProgressivaClementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva
finance.yahoo.com - December 12 at 9:14 AM
Zacks: Clementia Pharmaceuticals Inc. (CMTA) Given $27.00 Average Target Price by AnalystsZacks: Clementia Pharmaceuticals Inc. (CMTA) Given $27.00 Average Target Price by Analysts
www.americanbankingnews.com - December 11 at 7:14 PM
Form 6-K Clementia Pharmaceutical For: Dec 05Form 6-K Clementia Pharmaceutical For: Dec 05
www.streetinsider.com - December 5 at 5:51 PM
 Clementia Pharmaceuticals Inc. (CMTA) Given $27.00 Average Target Price by Brokerages Clementia Pharmaceuticals Inc. (CMTA) Given $27.00 Average Target Price by Brokerages
www.americanbankingnews.com - November 21 at 11:50 PM
Q4 2017 Earnings Forecast for Clementia Pharmaceuticals Inc. Issued By Wedbush (CMTA)Q4 2017 Earnings Forecast for Clementia Pharmaceuticals Inc. Issued By Wedbush (CMTA)
www.americanbankingnews.com - November 17 at 10:40 PM
Clementia Pharmaceuticals (CMTA) Outperform Rating Reiterated at WedbushClementia Pharmaceuticals' (CMTA) Outperform Rating Reiterated at Wedbush
www.americanbankingnews.com - November 14 at 4:00 PM
Clementia Reports Third Quarter 2017 Financial Results and Business HighlightsClementia Reports Third Quarter 2017 Financial Results and Business Highlights
finance.yahoo.com - November 13 at 10:35 PM
 Analysts Set $27.00 Target Price for Clementia Pharmaceuticals Inc. (CMTA) Analysts Set $27.00 Target Price for Clementia Pharmaceuticals Inc. (CMTA)
www.americanbankingnews.com - November 6 at 9:58 AM
 Clementia Pharmaceuticals Inc. (CMTA) Given Average Recommendation of "Strong Buy" by Analysts Clementia Pharmaceuticals Inc. (CMTA) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - October 22 at 2:46 AM
Have Investors Already Priced In Healthcare Growth For Clementia Pharmaceuticals Inc (CMTA)?Have Investors Already Priced In Healthcare Growth For Clementia Pharmaceuticals Inc (CMTA)?
finance.yahoo.com - October 20 at 6:50 PM
Zacks: Clementia Pharmaceuticals Inc. (CMTA) Given Consensus Rating of "Strong Buy" by BrokeragesZacks: Clementia Pharmaceuticals Inc. (CMTA) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - October 15 at 9:04 AM
Clementia Pharmaceuticals to Participate in Upcoming Investor ConferencesClementia Pharmaceuticals to Participate in Upcoming Investor Conferences
finance.yahoo.com - September 6 at 5:17 PM
Clementia Pharms (CMTA) Quiet Period Will Expire  on September 11thClementia Pharm's (CMTA) Quiet Period Will Expire on September 11th
www.americanbankingnews.com - September 4 at 1:14 AM
 Clementia Pharm (CMTA) Given Consensus Rating of "Strong Buy" by Analysts Clementia Pharm (CMTA) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - September 1 at 2:34 PM
Clementia Announces Data Presentations at Upcoming Medical Conferences in SeptemberClementia Announces Data Presentations at Upcoming Medical Conferences in September
finance.yahoo.com - August 31 at 5:14 PM
Clementia Pharm (CMTA) Now Covered by BTIG ResearchClementia Pharm (CMTA) Now Covered by BTIG Research
www.americanbankingnews.com - August 31 at 7:46 AM
Clementia Pharm (CMTA) to Post Q3 2017 Earnings of ($0.32) Per Share, Leerink Swann ForecastsClementia Pharm (CMTA) to Post Q3 2017 Earnings of ($0.32) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - August 30 at 6:50 AM
Equities Analysts Offer Predictions for Clementia Pharms Q3 2017 Earnings (CMTA)Equities Analysts Offer Predictions for Clementia Pharm's Q3 2017 Earnings (CMTA)
www.americanbankingnews.com - August 30 at 6:50 AM

SEC Filings

Clementia Pharmaceuticals (NASDAQ:CMTA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Clementia Pharmaceuticals (NASDAQ:CMTA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Clementia Pharmaceuticals (NASDAQ CMTA) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.